Skip to main content
. 2019 Jun 19;68(9):1853–1860. doi: 10.2337/db19-0358

Table 1.

Baseline characteristics (unweighted and weighted) of the DCCT subcohort (n = 518) versus the full DCCT cohort (n = 1,441), and the baseline summaries of the three biomarkers

Unweighted Weighted* Full cohort
Age (years) 27 (22, 32) 27 (21, 32) 27 (22, 32)
Diabetes duration (months) 55 (30, 115) 50 (29, 107) 51 (28, 109)
AER (mg/24 h) 11.5 (7.2, 18.7) 11.5 (7.2, 18.7) 11.5 (7.2, 18.7)
eGFR (mL/min/1.73 m2) 124.8 (117.9, 133.1) 124.9 (117.9, 133.9) 125 (118, 134)
BMI (kg/m2) 23.4 (21.6, 25.3) 23.3 (21.5, 25.3) 23.3 (21.5, 25.2)
Triglycerides (mg/dL) 70 (54, 93) 69 (54, 91) 70 (55, 94)
LDL (mg/dL) 105 (88, 126) 104 (87, 124) 107 (91, 127)
HDL (mg/dL) 48 (42, 57) 50 (42, 57) 49 (42, 57)
SBP (mmHg) 114 (108, 122) 114 (108, 122) 114 (108, 122)
Diastolic blood pressure (mmHg) 74 (68, 80) 74 (68, 80) 72 (68, 80)
Pulse (bpm) 76 (68, 84) 76 (68, 84) 76 (68, 84)
HbA1c (%; mmol/mol) 8.6 (7.6, 9.8); 70 (60, 84) 8.5 (7.6, 9.8); 69 (60, 84) 8.7 (7.8, 9.9); 72 (62, 85)
Treatment group (% intensive) 46.3 48.7 49.3
Cohort (% primary) 45.2 50.0 50.4
Sex (% male) 52.3 52.9 52.8
Smoking (%) 19.3 18.4 18.5
AGE-LDL-IC (mg/L) 6.4 (2.6, 12) 5.8 (2.5, 10.8)
MDA-LDL-IC (mg/L) 107.3 (42.7, 195.9) 98.5 (37.4, 185.9)
oxLDL-IC (mg/L) 161.7 (88.6, 295.3) 149.4 (80.8, 265.9)

Data are median (quartile 1, quartile 3) unless otherwise indicated.

*With weights based on the joint distribution of the complications and further adjusted for sex and cohort.